Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Amivantamab-vmjw + Lazertinib + rHuPH20|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Amivantamab-vmjw||Rybrevant||JNJ-61186372||EGFR Antibody 53 MET Antibody 27||Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy (FDA.gov).|
|Lazertinib||GNS 1480|YH25448|JNJ-73841937|JNJ73841937|JNJ 73841937|YH 25448|YH-25448||EGFR Inhibitor 3rd gen 26||Lazertinib (YH25448) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977).|
|rHuPH20||Hylenex||rHuPH20 is recombinant human hyaluronidase lacking the GPI anchor domain, which may enhance dispersion of substances delivered subcutaneously (PMID: 25967925, PMID: 16876899, PMID: 30744432).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04606381||Phase I||Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20||A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA)||Recruiting||USA | GBR | CAN||1|